Recruiting PHASE1 INTERVENTIONAL 2-arm NCT05701488

SIRT With Tremelimumab and Durvalumab for Resectable HCC

A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma

Sponsor: AstraZeneca

Conditions Hepatocellular Cancer Hepatocellular Carcinoma Resectable Hepatocellular Carcinoma

Interventions Durvalumab SIRT Tremelimumab

Updated 6 times since 2023 Last updated: Aug 26, 2025 Started: Apr 21, 2023 Primary completion: Oct 1, 2026 Completion: Oct 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hepatocellular Cancer and Hepatocellular Carcinoma and is currently actively recruiting participants. AstraZeneca leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Jiping Wang, MD, PhD
Sirtex Medical

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Los Angeles, United States